--- a
+++ b/clusters/3009knumclusters/centers.txt
@@ -0,0 +1,300 @@
+Cluster 0: cypa strong inhibitors inducers cytochrome subfamily family polypeptide medications moderate
+Cluster 1: infection requiring systemic active therapy antibiotics antibiotic intravenous treatment days
+Cluster 2: transaminase serum aminotransferase glutamic oxaloacetic sgot sgpt upper normal pyruvate
+Cluster 3: bilirubin mg dl total syndrome gilberts gilbert serum direct unless
+Cluster 4: investigational participated study device participating currently agent weeks therapy dose
+Cluster 5: phase ii patients aim prior expansion cohort portion study treatment
+Cluster 6: creatinine clearance min ml serum mg dl estimated uln crcl
+Cluster 7: consent informed procedures study specific provide written prior signed ability
+Cluster 8: metastasis brain leptomeningeal known distant patients symptomatic suspected cns evidence
+Cluster 9: expectancy life weeks greater patients estimated years equal investigator year
+Cluster 10: women contraception men childbearing potential use adequate unwilling pregnant study
+Cluster 11: cardiac significant disease arrhythmia function history impaired arrhythmias requiring uncontrolled
+Cluster 12: hiv positive known immunodeficiency virus human infection patients cd aids
+Cluster 13: contraceptive use potential effective reproductive method study methods men agreed
+Cluster 14: qtc interval qt msec corrected prolongation ecg electrocardiogram prolonged milliseconds
+Cluster 15: males females years age older aged time consent old non
+Cluster 16: hemoglobin dl transfusion days mmol prior transfusions registration erythropoietin transfused
+Cluster 17: hgb hemoglobin dl transfusion achieve intervention acceptable days note use
+Cluster 18: hemoglobin dl mmol gm hb mg greater level weeks phase
+Cluster 19: platelets mm cells days anc prior transfusion registration obtained plt
+Cluster 20: received prior therapy patients treatment previously systemic days study weeks
+Cluster 21: heart angina myocardial infarction unstable congestive failure cardiac months uncontrolled
+Cluster 22: hepatitis virus immunodeficiency hiv human infection known active hcv hbv
+Cluster 23: cancer cell basal squamous adequately skin treated years situ malignancy
+Cluster 24: granulocyte colony stimulating csf factor count mm absolute factors macrophage
+Cluster 25: surgery prior patients weeks days radiation patient major treatment planned
+Cluster 26: breast cancer invasive diagnosis prior patients inflammatory metastatic carcinoma dcis
+Cluster 27: pregnancy lactation breastfeeding current test positive women testing time standards
+Cluster 28: neutrophil absolute count anc mm cells days registration prior support
+Cluster 29: signed informed consent written form dated patient guardian study document
+Cluster 30: ecog performance status appendix patients score scale equal adequate patient
+Cluster 31: feeding breast pregnant women females pregnancy female patients lactating planning
+Cluster 32: samples research provide purposes correlative blood willing tissue mandatory willingness
+Cluster 33: corticosteroids inhaled topical steroids systemic prednisone immunosuppressive mg doses daily
+Cluster 34: ps ecog performance eastern cooperative oncology group status score scale
+Cluster 35: bone marrow function adequate involvement cells blood biopsy patients prior
+Cluster 36: organ transplant history allogeneic solid allograft allografts corneal marrow bone
+Cluster 37: childbearing potential pregnancy test negative female serum females urine prior
+Cluster 38: illness compliance social requirements psychiatric intercurrent situations uncontrolled limit study
+Cluster 39: platelets ul plt ml microliter cells days transfusion registration prior
+Cluster 40: mcl platelets days initiation performed treatment registration prior transfusion obtained
+Cluster 41: bilirubin upper normal limit total uln institutional times gilberts syndrome
+Cluster 42: ul platelet count lymphocyte neutrophils transfusion independent days obtained prior
+Cluster 43: measurable disease evaluable lesion patients non defined cm lesions criteria
+Cluster 44: pregnant women excluded study patients planning currently female females patient
+Cluster 45: grade toxicity alopecia toxicities prior therapy related recovered resolved previous
+Cluster 46: platelet mm count days cells transfusion prior transfusions obtained independent
+Cluster 47: interstitial lung pneumonitis disease history evidence active infectious pulmonary ild
+Cluster 48: contraception methods intrauterine barrier device method use condom potential effective
+Cluster 49: therapy steroid immunosuppressive form systemic receiving immunodeficiency diagnosis dose days
+Cluster 50: therapies prior received number anti patients therapy cancer anticancer treatment
+Cluster 51: rituximab containing prior therapy treatment regimen refractory months received chemotherapy
+Cluster 52: effects recovered prior toxic therapy acute fully grade chemotherapy radiotherapy
+Cluster 53: pressure mmhg blood systolic diastolic hypertension bp uncontrolled controlled antihypertensive
+Cluster 54: pd programmed anti death ligand cell lymphocyte ctla antibody cytotoxic
+Cluster 55: bleeding diathesis active history disorder disorders gastrointestinal known significant evidence
+Cluster 56: hemorrhage intracranial stroke months history enrollment prior hemoptysis study dose
+Cluster 57: fraction ejection left ventricular lvef cardiac echocardiogram shortening lower normal
+Cluster 58: willingness understand sign ability written document informed consent subjects subject
+Cluster 59: aminotransferase ast alt aspartate alanine uln upper normal limit times
+Cluster 60: eastern cooperative oncology group ecog performance status karnofsky score scale
+Cluster 61: bowel gastrointestinal malabsorption resection vomiting absorption nausea small significantly disease
+Cluster 62: pneumonitis organizing fibrosis idiopathic pneumonia induced pulmonary history chest obliterans
+Cluster 63: transplant stem cell allogeneic autologous prior hematopoietic months received patients
+Cluster 64: inr normalized ratio international time uln prothrombin pt thromboplastin partial
+Cluster 65: days prior registration study therapy treatment dose radiotherapy enrollment growth
+Cluster 66: study pregnant inform suspect immediately agree contraception woman barrier duration
+Cluster 67: histologically confirmed cytologically adenocarcinoma diagnosis prostate metastatic cancer nsclc cell
+Cluster 68: compliance psychological safety condition protocol study conditions psychiatric medical procedures
+Cluster 69: staff medical regimens conduct history noncompliance compliance study planning non
+Cluster 70: concurrent therapy investigational agents chemotherapy cancer treatment use immunotherapy anti
+Cluster 71: ct pet tomography scan computed emission positron imaging mri disease
+Cluster 72: vaccines live attenuated influenza flu seasonal allowed inactivated intranasal vaccine
+Cluster 73: mcl neutrophil absolute count anc days initiation performed treatment registration
+Cluster 74: mm longest measured measurable accurately lesion dimension diameter ct recorded
+Cluster 75: bacterial fungal viral infection active uncontrolled infections systemic requiring antibiotics
+Cluster 76: patients eligible study excluded therapy prior treated treatment receiving receive
+Cluster 77: hodgkin lymphoma non nhl cell refractory relapsed classical autologous confirmed
+Cluster 78: english read speak speaking able understand write spanish ability language
+Cluster 79: imaging resonance magnetic mri ct tomography computed scan disease brain
+Cluster 80: inability comply procedures unwillingness follow protocol study swallow requirements pills
+Cluster 81: hepatitis positive virus hcv antibody hbv antigen surface infection test
+Cluster 82: ctcae grade nci neuropathy hemorrhage version event bleeding diarrhea alopecia
+Cluster 83: trial confound best abnormality results interfere participate laboratory duration current
+Cluster 84: vascular peripheral aortic disease aneurysm significant arterial repair thrombosis collagen
+Cluster 85: organ function adequate marrow defined hematologic end laboratory bone days
+Cluster 86: brain metastases known patients treated stable trial excluded clinical evidence
+Cluster 87: protein urine ratio mg hour serum light dl proteinuria chain
+Cluster 88: illness medical psychiatric interfere condition prevent opinion abnormality potentially likely
+Cluster 89: carcinoma cell skin basal squamous situ malignancy years cervix treated
+Cluster 90: expecting conceive trial projected screening children father visit breastfeeding duration
+Cluster 91: monoclonal antibody reaction hypersensitivity severe history antibodies reactions infusion mab
+Cluster 92: half lives shorter whichever investigational prior weeks days drug therapy
+Cluster 93: disease progression progressive patients evidence leptomeningeal therapy refractory treatment prior
+Cluster 94: participant research study received treatment therapy prior disease receiving investigator
+Cluster 95: sarcoma soft tissue ewing oncogene homolog tumor diagnosis confirmed rhabdomyosarcoma
+Cluster 96: albumin dl serum mg days initiation treatment performed gm registration
+Cluster 97: unable unwilling protocol comply follow requirements study consent patients abide
+Cluster 98: live vaccine days attenuated received prior dose study vaccination receipt
+Cluster 99: tissue tumor biopsy archival available sample slides obtained fresh paraffin
+Cluster 100: leukemia aml promyelocytic acute apl mds myeloid diagnosis myelodysplastic patients
+Cluster 101: immunodeficiency hiv virus human known positive infection history antibodies acquired
+Cluster 102: platinum based chemotherapy regimen disease progression therapy line prior resistant
+Cluster 103: contraindication contrast mri hypersensitivity known drugs allergy concomitant including gadolinium
+Cluster 104: surgically childbearing sterile potential abstain heterosexual activity sterilized study subjects
+Cluster 105: limits normal institutional bilirubin total upper creatinine serum potassium uln
+Cluster 106: chemotherapy prior received cytotoxic patients regimen treatment cancer regimens systemic
+Cluster 107: bilirubin uln total direct serum syndrome gilbert gilberts levels subjects
+Cluster 108: normal limit upper creatinine uln serum times institutional alt ast
+Cluster 109: lactating pregnant women females female patients breastfeeding study excluded subject
+Cluster 110: alcohol abuse drug history substance current known dependence active illicit
+Cluster 111: risk high intermediate ipss mds prognostic scoring international patients disease
+Cluster 112: healing wound fracture ulcer non bone presence major days active
+Cluster 113: diagnosed newly cancer malignancy patients years previously disease nonmelanoma residual
+Cluster 114: therapy prior anti chemotherapy systemic cancer hormonal treatment patients radiation
+Cluster 115: weeks earlier administered adverse events recovered agents prior entering study
+Cluster 116: recist measurable disease version criteria defined according lesion evaluable based
+Cluster 117: inhibitor prior treatment kinase therapy received parp mek cdk mtor
+Cluster 118: radiation therapy prior weeks chemotherapy treatment patients study received palliative
+Cluster 119: white wbc blood cell cells ul count mm mcl days
+Cluster 120: stage iv iii cancer disease ajcc melanoma ii breast nsclc
+Cluster 121: bmi mass index body kg obese overweight greater patients weight
+Cluster 122: function adequate liver renal marrow bone kidney defined hematological inadequate
+Cluster 123: tumor biopsy primary cm patients biopsies solid accessible size resection
+Cluster 124: aptt activated thromboplastin partial ptt anticoagulant intended anticoagulants time pt
+Cluster 125: receptor er ihc negative estrogen positive progesterone hybridization fish breast
+Cluster 126: tuberculosis tb bacillus active known history previous clinical diagnosis latent
+Cluster 127: inclusion criteria apply meet registration cohort patients additional specific protocol
+Cluster 128: infections active uncontrolled requiring antibiotics systemic illnesses opportunistic patients medical
+Cluster 129: cr remission complete induction response aml leukemia pr patients relapse
+Cluster 130: heparin low molecular weight warfarin anticoagulation therapeutic aspirin dose lmwh
+Cluster 131: concurrently investigational receiving agents study patients therapy treatment agent using
+Cluster 132: glioma world organization grade health glioblastoma diagnosis histologically confirmed iv
+Cluster 133: contraception use effective agree potential study childbearing male method female
+Cluster 134: drug study dose days administration prior weeks investigational therapy experimental
+Cluster 135: ischemic transient thrombosis attack cerebrovascular accident deep months embolism history
+Cluster 136: qt long syndrome congenital history family qtc interval msec corrected
+Cluster 137: cancer diagnosis lung ovarian small cell primary center patients non
+Cluster 138: pembrolizumab excipients hypersensitivity severe known grade epacadostat substance active history
+Cluster 139: months survival prior past expected enrollment study history treatment therapy
+Cluster 140: pulmonary obstructive disease chronic severe requiring copd antibiotics hospitalization history
+Cluster 141: common terminology adverse ctcae events grade criteria version institute national
+Cluster 142: hla donor matched leukocyte antigen unrelated drb related typing human
+Cluster 143: treatment prior previous study patients weeks therapy allowed dose anti
+Cluster 144: consent informed able sign understand willing written form document patient
+Cluster 145: fasting glucose mg dl mmol triglycerides cholesterol serum plasma diabetes
+Cluster 146: agents investigational receiving patients currently participants study anti eligible cancer
+Cluster 147: equal greater years age dl count platelets hemoglobin mm platelet
+Cluster 148: inhibitors prior kinase treatment tyrosine therapy mtor patients use pik
+Cluster 149: nervous central cns metastases active known untreated disease meningitis lymphoma
+Cluster 150: hepatitis active infection known chronic hiv history positive viral patients
+Cluster 151: step registration prior randomization days eligibility crossover criteria dl patients
+Cluster 152: pneumonitis infectious non history steroids required current evidence active known
+Cluster 153: egfr alk mutation tki exon kinase mutations epidermal receptor treatment
+Cluster 154: leukemia acute plasma chronic cell lymphoblastic myeloid myelogenous lymphoma cml
+Cluster 155: response criteria recist solid evaluation tumors measurable disease version evaluable
+Cluster 156: capacity forced predicted dlco carbon monoxide fev expiratory volume diffusing
+Cluster 157: test pregnancy negative urine serum positive female hours confirmed study
+Cluster 158: laboratory values parameters clinical following abnormalities study places clia range
+Cluster 159: fcbp agree contact sexual vasectomy condom latex successful potential lenalidomide
+Cluster 160: absorption gastrointestinal gi interfere disease alter oral malabsorption significantly disorders
+Cluster 161: diabetes mellitus type uncontrolled controlled poorly ac insulin hbac glucose
+Cluster 162: autoimmune disease active history systemic past requiring suspected vitiligo immunosuppressive
+Cluster 163: major surgery weeks prior study days recovered drug dose effects
+Cluster 164: hamster chinese ovary hypersensitivity recombinant products antibodies known human cell
+Cluster 165: stable dose decreasing corticosteroids prior days patients weeks corticosteroid enrollment
+Cluster 166: time pt prothrombin thromboplastin ptt partial inr uln normalized ratio
+Cluster 167: consent informed written voluntary sign guidelines nature legal accordance patients
+Cluster 168: month prior therapy study investigational treatment patients enrollment hemoptysis use
+Cluster 169: hormone releasing lhrh luteinizing therapy agonist thyroid androgen orchiectomy gnrh
+Cluster 170: investigational agent days treatment study prior weeks received drug receiving
+Cluster 171: hypersensitivity known excipients components history component drugs study formulation excipient
+Cluster 172: weeks prior radiotherapy therapy chemotherapy study treatment dose nitrosoureas mitomycin
+Cluster 173: illness pectoris social situations intercurrent arrhythmia uncontrolled compliance congestive limited
+Cluster 174: pugh child class score hepatic impairment cirrhosis liver severe classification
+Cluster 175: advanced locally metastatic unresectable disease histologically cancer confirmed solid recurrent
+Cluster 176: creatinine calculated clearance min ml serum measured uln crcl mg
+Cluster 177: allergy known hypersensitivity components history study excipients formulations drug formulation
+Cluster 178: score karnofsky lansky performance years age patients kps ambulatory wheelchair
+Cluster 179: bearing child potential pregnancy test women negative pregnant serum female
+Cluster 180: retinal rvo occlusion vein history evidence current retinopathy serous risk
+Cluster 181: following criteria meet patients treatment disease prior therapy defined progression
+Cluster 182: history primary immunodeficiency disease prior known hypertensive pancreatitis leptomeningeal patients
+Cluster 183: hepatitis reactive qualitative hbsag rna detected hcv ribonucleic surface acid
+Cluster 184: creatinine uln serum times institutional renal days registration obtained prior
+Cluster 185: lymph node nodes axillary sentinel cm biopsy dissection disease regional
+Cluster 186: significant clinically disease cardiac history uncontrolled pulmonary investigator active ecg
+Cluster 187: seizure disorder history patients seizures medication brain requiring uncontrolled controlled
+Cluster 188: adjuvant chemotherapy neoadjuvant therapy prior setting months metastatic neo treatment
+Cluster 189: hypertension uncontrolled diabetes controlled despite pulmonary poorly history medical hypertensive
+Cluster 190: pacemaker metal implanted clips implants mri metallic devices pacemakers aneurysm
+Cluster 191: age years time patients consent donor men old lansky women
+Cluster 192: liver uln disease metastases chronic cirrhosis alt ast hepatitis patients
+Cluster 193: inappropriate make judgment study investigator severe interfere patient entry increase
+Cluster 194: donor donors matched unrelated related blood cell infusion lymphocyte haploidentical
+Cluster 195: nursing pregnant women female patients females excluded lactating study mothers
+Cluster 196: mg dl creatinine serum years age maximum male calcium female
+Cluster 197: hepatic function adequate renal marrow bone defined hematological coagulation cardiac
+Cluster 198: breastfeeding pregnant women females female patients excluded patient subject study
+Cluster 199: return follow institution enrolling willing monitoring phase active mayo study
+Cluster 200: mri contrast undergo ct patients unable brain scan imaging contraindications
+Cluster 201: filtration glomerular rate min ml gfr creatinine estimated clearance renal
+Cluster 202: malignancy active years history concurrent treatment second prior requiring patients
+Cluster 203: carcinoma cell squamous small urothelial adenocarcinoma histologically clear histology renal
+Cluster 204: alkaline phosphatase uln limit normal upper liver alp times bone
+Cluster 205: pelvic radiation prior radiotherapy irradiation previous abdominal therapy history patients
+Cluster 206: hematologic function adequate renal hepatic inadequate coagulation liver defined toxicity
+Cluster 207: autoimmune requiring psoriasis vitiligo diabetes recur hypothyroidism trigger type mellitus
+Cluster 208: msec qtcf interval fridericia qt formula corrected ecg screening correction
+Cluster 209: disease inflammatory bowel colitis autoimmune ulcerative history arthritis systemic lupus
+Cluster 210: swallow capsules tablets able unable patients inability intact pills ability
+Cluster 211: cord spinal compression brain metastases leptomeningeal untreated symptomatic stable disease
+Cluster 212: expectancy life months greater estimated investigator opinion patients anticipated predicted
+Cluster 213: involvement nervous central cns known active lymphoma leukemia patients malignancy
+Cluster 214: creatinine institutional clearance normal levels min ml uln upper calculated
+Cluster 215: recovered therapy prior grade note molecule complications targeted administered adequately
+Cluster 216: neuropathy grade peripheral sensory pain motor greater existing higher patients
+Cluster 217: immediate reaction hypersensitivity idiosyncrasy chemically delayed drugs related dmso excipients
+Cluster 218: platelet count mcl days transfusion prior transfusions plt dl ml
+Cluster 219: board review irb approved institutional consent informed sign understand written
+Cluster 220: cancer skin non melanoma malignancy situ years carcinoma cervix invasive
+Cluster 221: infection active uncontrolled patients ongoing antibiotics eligible presence evidence systemic
+Cluster 222: composition compounds chemical similar attributed allergic reactions biologic history used
+Cluster 223: products hypersensitivity blood known murine investigational tobacco containing study allergy
+Cluster 224: contraception dose study agree male method adequate abstinence use starting
+Cluster 225: karnofsky performance status kps scale score lansky patients greater ecog
+Cluster 226: transaminase aminotransferase serum uln sgpt glutamic sgot alt oxaloacetic alanine
+Cluster 227: cll lymphocytic sll leukemia chronic iwcll diagnosis lymphoma transformation treatment
+Cluster 228: psa ng ml prostate rising progression value specific antigen prostatectomy
+Cluster 229: years older age male female aged patients subjects time consent
+Cluster 230: exclusion criteria registration apply cohort treatment specific patients tnbc pre
+Cluster 231: myeloma multiple diagnosis relapsed refractory imwg therapy criteria working prior
+Cluster 232: interfere results study interpretation condition medical investigator participation opinion evaluation
+Cluster 233: oxygen air room pulse oximetry saturation supplemental rest dyspnea pulmonary
+Cluster 234: cooperation substance abuse disorders interfere psychiatric requirements trial known study
+Cluster 235: rems program revlimid registered mandatory comply willing requirements mitigation able
+Cluster 236: myocardial infarction months angina unstable history prior coronary study stroke
+Cluster 237: uncontrolled medical severe disease active infection conditions seizures concurrent disorder
+Cluster 238: eligibility criteria medi phase cohort ii study cancer meet registration
+Cluster 239: altered prohibit understanding mental rendering dementia consent informed status psychiatric
+Cluster 240: oral medications able medication inability ability patients absorption gastrointestinal tolerate
+Cluster 241: standard therapy care advanced solid metastatic refractory available histologically confirmed
+Cluster 242: weight loss months hearing lbs body past pounds unintentional program
+Cluster 243: opinion condition investigator medical study subject compromise patient participation safety
+Cluster 244: comply visits procedures willing able study scheduled follow protocol ability
+Cluster 245: mg equivalent prednisone day dose corticosteroids daily corticosteroid systemic steroids
+Cluster 246: hcc hepatocellular diagnosis systemic carcinoma sorafenib prior fibrolamellar confirmed liver
+Cluster 247: treated situ cancer adequately carcinoma curatively years curative intent malignancy
+Cluster 248: antiretroviral combination hiv immunodeficiency positive ineligible virus human therapy patients
+Cluster 249: metformin taking hypersensitivity reason subjects insulin currently known patients doxycycline
+Cluster 250: muga fraction echocardiogram acquisition ejection scan gated left ventricular lvef
+Cluster 251: abdominal perforation fistula gastrointestinal abscess intra history months obstruction gi
+Cluster 252: women pregnancy test childbearing negative potential serum days prior urine
+Cluster 253: cns metastases nervous central patients disease stable symptomatic treated brain
+Cluster 254: lymphoma cell large follicular diffuse dlbcl mantle zone refractory marginal
+Cluster 255: longer whichever half lives investigational drug days study prior treatment
+Cluster 256: pd inhibitor ctla prior anti treatment therapy including durvalumab previous
+Cluster 257: blasts marrow bone leukemia aml blood mds peripheral refractory patients
+Cluster 258: cardiovascular significant disease clinically uncontrolled history including evidence pulmonary condition
+Cluster 259: traumatic injury major procedure significant surgical open biopsy days study
+Cluster 260: prostate cancer adenocarcinoma prior biopsy therapy diagnosis treatment prostatectomy chemotherapy
+Cluster 261: replacement systemic modifying thyroxine pituitary disease autoimmune insulin physiologic adrenal
+Cluster 262: surgical procedure resection major prior days study weeks biopsy patients
+Cluster 263: syndrome myelodysplastic history poems malabsorption organomegaly endocrinopathy polyneuropathy gilbert changes
+Cluster 264: severe infection immunodeficiency disease moderate pneumonia bacteremia hospitalization impairment complications
+Cluster 265: metastatic disease evidence patients distant prior chemotherapy therapy recurrent cancer
+Cluster 266: provide consent informed written able willing trial assent ability patients
+Cluster 267: host graft gvhd versus disease transplant active stem allogeneic acute
+Cluster 268: wort st phenytoin carbamazepine phenobarbital cypa rifampin johns inducers rifabutin
+Cluster 269: kg body weight area surface bsa cells cd weigh patients
+Cluster 270: ms qt interval corrected qtc qtcf fridericia mean correction ecg
+Cluster 271: use medications prohibited medication drugs taking current study prior concomitant
+Cluster 272: ventricular heart arrhythmias fibrillation uncontrolled history myocardial block infarction failure
+Cluster 273: zubrod performance status patients registration days prior step ps karnofsky
+Cluster 274: patient study subjects prior diagnosis participants subject clinical known blood
+Cluster 275: birth control potential effective use study method agree childbearing women
+Cluster 276: start treatment prior study weeks days trial investigational therapy radiotherapy
+Cluster 277: hcg chorionic gonadotropin beta human test pregnancy negative women potential
+Cluster 278: neck head radiation squamous carcinoma cancer cell prior therapy cavity
+Cluster 279: physical examination activity history registration compulsorily detained days prior exam
+Cluster 280: immunosuppressive systemic corticosteroids medications therapy treatment chronic use medication agents
+Cluster 281: creatinine gault cockcroft clearance min ml formula calculated using equation
+Cluster 282: access venous internet computer telephone central placement phone adequate sampling
+Cluster 283: bilateral hysterectomy oophorectomy potential consecutive postmenopausal months childbearing tubal undergone
+Cluster 284: leukocytes mcl ul mm microliter days registration obtained ml phase
+Cluster 285: swallow oral retain able medication ability pills medications orally bowels
+Cluster 286: finding metabolic reasonable suspicion contraindicates examination render dysfunction physical giving
+Cluster 287: testosterone ng dl castrate serum level nmol levels castration androgen
+Cluster 288: mother breastfeeding discontinued pregnant excluded women treated study agents potential
+Cluster 289: coagulopathy bleeding diathesis evidence history anticoagulation significant therapeutic absence disorder
+Cluster 290: requirements comply able study protocol adhere schedule visit monitoring safety
+Cluster 291: anti pd ctla antibody prior therapy received checkpoint targeting agent
+Cluster 292: ul neutrophil absolute count anc cells days peripheral registration prior
+Cluster 293: hg pressure mm blood systolic hypertension diastolic uncontrolled bp despite
+Cluster 294: lipase amylase uln serum pancreatitis radiologic normal clinical pancreatic evidence
+Cluster 295: allergic reactions reaction history anaphylactic severe hypersensitivity humanized proteins antibodies
+Cluster 296: transplantation allogeneic stem organ cell prior solid autologous hematopoietic marrow
+Cluster 297: warfarin anticoagulation vitamin antagonists therapeutic use patients receiving concomitant requires
+Cluster 298: pleural ascites effusion effusions pericardial requiring paracentesis drainage clinically thoracentesis
+Cluster 299: heart york association new failure class congestive nyha iv iii